Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

  • Revenue in USD (TTM)55.09bn
  • Net income in USD-288.00m
  • Incorporated1942
  • Employees88.00k
  • Location
    Pfizer Inc66 HUDSON BOULEVARD EASTNEW YORK 10001-2192United StatesUSA
  • Phone+1 (212) 733-2323
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pfizer.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gilead Sciences, Inc.27.45bn484.00m83.83bn18.00k187.134.7826.183.050.35960.359621.8914.080.46463.886.221,525,000.000.77186.740.96248.1275.7878.641.6616.950.936513.670.590781.22-0.60484.1523.370.7436-8.745.64
Bristol-Myers Squibb Co45.53bn-6.15bn85.69bn34.10k--5.2022.981.88-3.10-3.1022.158.140.47113.925.181,335,308.00-6.353.05-8.273.7675.9476.13-13.477.690.994715.570.7709133.63-2.5014.8126.8410.034.927.34
Regeneron Pharmaceuticals Inc13.10bn3.86bn109.52bn13.45k29.354.0625.518.3633.8633.86114.89244.930.40670.69742.53973,985.1011.9820.1813.3623.2286.3286.6329.4538.114.51--0.091--7.7614.34-8.8710.7219.32--
Vertex Pharmaceuticals Incorporated10.19bn4.02bn114.06bn5.40k28.676.1627.0611.2015.4215.4239.0671.800.47491.986.101,886,111.0018.7419.9222.2923.6486.8687.6739.4635.853.29--0.01910.0010.5126.498.9646.5022.02--
Pfizer Inc55.09bn-288.00m161.84bn88.00k--1.7525.752.94-0.0608-0.06459.7116.280.26441.594.73626,056.80-0.12198.20-0.149810.4070.4569.34-0.46122.680.7784--0.42960.11-41.707.46-93.20-7.9412.213.82
Amgen Inc29.53bn3.76bn168.90bn26.70k44.9933.6320.275.727.007.0054.979.360.32511.454.721,106,067.004.1410.365.0913.0666.3875.4112.7426.510.97932.460.927359.547.093.492.52-4.368.5410.04
Data as of May 23 2024. Currency figures normalised to Pfizer Inc's reporting currency: US Dollar USD

Institutional shareholders

31.50%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2024482.07m8.54%
SSgA Funds Management, Inc.as of 31 Mar 2024290.70m5.15%
BlackRock Fund Advisorsas of 31 Mar 2024281.53m4.99%
Wellington Management Co. LLPas of 31 Mar 2024177.70m3.15%
Charles Schwab Investment Management, Inc.as of 31 Mar 2024122.24m2.17%
Geode Capital Management LLCas of 31 Mar 2024113.58m2.01%
Capital Research & Management Co. (World Investors)as of 31 Mar 2024112.66m2.00%
Norges Bank Investment Managementas of 31 Dec 202373.98m1.31%
Massachusetts Financial Services Co.as of 31 Mar 202469.55m1.23%
State Farm Investment Management Corp.as of 31 Mar 202454.51m0.97%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.